(Q37408655)

20 August 2017

Exploratory analysis of serum CA-125 response to surgery and the risk of relapse in patients with FIGO stage IIIC ovarian cancer (English)

1 reference

20 August 2017

1 reference

10

Dennis S Chi

1 reference

20 August 2017

9

Richard R Barakat

1 reference

20 August 2017

8

Ginger J Gardner

1 reference

20 August 2017

1

Oliver Zivanovic

1 reference

20 August 2017

3

Alexia Iasonos

1 reference

20 August 2017

7

Douglas A Levine

1 reference

20 August 2017

5

Paul J Sabbatini

1 reference

20 August 2017

2

Camelia S Sima

1 reference

20 August 2017

Katherine M Bell-McGuinn

series ordinal

4

object named as

Katherine M Bell-McGuinn

1 reference

20 August 2017

Mario M Leitao

6

1 reference

20 August 2017

language of work or name

English

0 references

publication date

7 August 2009

1 reference

20 August 2017

1 reference

20 August 2017

115

1 reference

20 August 2017

2

1 reference

20 August 2017

209-214

1 reference

The prognostic value of pretreatment CA 125 in patients with advanced ovarian carcinoma: a Gynecologic Oncology Group study

20 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3870341

New insights into the pathogenesis of serous ovarian cancer and its clinical impact

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3870341

6 September 2017

Cancer statistics, 2008

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3870341

Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3870341

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3870341

Reactivity of a monoclonal antibody with human ovarian carcinoma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3870341

A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3870341

The relationship between postoperative decline of serum CA 125 levels and size of residual disease after initial surgery in patients with advanced ovarian cancer: a CTF study

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3870341

Serum half-life of CA 125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: results of a multicentric Italian study

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3870341

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3870341

Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer).

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3870341

Improved survival in women with BRCA-associated ovarian carcinoma

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3870341

Does the nadir CA125 concentration predict a long-term outcome after chemotherapy for carcinoma of the ovary?

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3870341

Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125

2 October 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.038

Ovarian cancer: the prognostic value of the serum half-life of CA125 during induction chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.038

CA 125 half-life and CA 125 nadir during induction chemotherapy are independent predictors of epithelial ovarian cancer outcome: results of a French multicentric study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.038

Significance of early changes in the serum CA-125 antigen level on overall survival in advanced ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.038

CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.038

Pretreatment CA-125 and risk of relapse in advanced ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.038

CA 125 serum levels in the early post-operative period do not reflect tumour reduction obtained by cytoreductive surgery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.038

Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.038

Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.038

Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.038

Clinical and Pathological Features of Ovarian Cancer in Women with Germ-Line Mutations ofBRCA1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.038

Clinicopathologic features of BRCA-linked and sporadic ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.038

[Does follow-up of false-negative CA-125 serum values in tumor after-care of ovarian cancer make sense?]

7 January 2021

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19664812

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1016/J.YGYNO.2009.06.038

1 reference

20 August 2017

1 reference

20 August 2017

PubMed publication ID

19664812

1 reference